TH73099A - Erysipelothrix Rhusiopathiae-Haemophilus Parasuis vaccine and how to use it. - Google Patents

Abstract

DC60 (20/01/48) This invention provides an improved single-dose combination and vaccine against E. rhusiopathiae and an improved single-dose vaccine against E. rhusiopathiae and H. parasuis that provides one or more of the following: 1) provides an immunogenic response against E. rhusiopathiae and/or H. parasuis; 2) reduces the risk of clinical manifestations of E. rhusiopathiae and/or H. parasuis infection; 3) induces an immune response against E. rhusiopathiae and/or H. parasuis; and 4) has a DOI (Dosage of Inhibition) against E. rhusiopathiae and/or H. parasuis; for at least four months. The E. rhusiopathiae combination or vaccine and the E. rhusiopathiae-H. parasuis combination or vaccine each contain a heat-inactivated bacterial component of E. rhusiopathiae and a substance Optimal synergistic action: Combined E. rhusiopathiae - H. parasuis mixtures or vaccines containing H. parasuis antigen can be administered to animals using commonly practiced methods. Intramuscular doses are typically less than 5 ml. The amount of E. rhusiopathiae and/or H. parasuis antigen in each dose should be sufficient to induce an immune response in the vaccinated or combined animal, maintaining immunity and minimizing the risk of clinical manifestations resulting from E. rhusiopathiae and/or H. parasuis infection for an optimal duration of immunity. This invention provides improved combinations and single doses of vaccines against E. rhusiopathiae and improved single doses of vaccines against E. rhusiopathiae and H. parasuis that deliver one or more of the following: 1) provide an effective immune response against E. rhusiopathiae and/or H. parasuis; 2) reduce the risk of clinical manifestations resulting from E. rhusiopathiae and/or H. parasuis infection; The vaccine must be administered if: 1) it has been found to infect animals with E. rhusiopathiae and/or H. parasuis; 2) it has been found to induce an immune response against E. rhusiopathiae and/or H. parasuis; 3) it has been found to induce an immune response against E. rhusiopathiae and/or H. parasuis; and 4) it has a DOI (Defective Inhibitory Illness) against E. rhusiopathiae and/or H. parasuis; for at least four months. E. rhusiopathiae mixtures or vaccines, and E. rhusiopathiae-H. parasuis mixtures or vaccines, contain heat-inactivated E. rhusiopathiae bacterial components and appropriate adjuvants. E. rhusiopathiae-H. parasuis mixtures or vaccines also contain a dose of H. parasuis antigen. Vaccination can be performed using standard methods. Intramuscular doses are typically less than 5 ml. The amount of E. rhusiopathiae and/or H. parasuis antigen in each dose should be sufficient to induce an immune response in the animal. Vaccinated patients or those receiving immunotherapy combinations are advised to maintain immunity and reduce the risk of clinical symptoms resulting from E. rhusiopathiae and/or H. parasuis infections for an appropriate duration of immunity.

Claims (41)

1. A mixture containing the following quantities of antigens: Erysipelothrix Rhusiopathiae; Haemophilus Parasuis; and an synergistic agent. 2. The mixture of claim 1 contains an amount of Erysipelothrix Rhusiopathiae antigen that is effective in reducing the risk of clinical manifestations of Erysipelothrix Rhusiopathiae infection when administered to susceptible animals. 3. The resulting mixture of claim 2, the effective amount of Erysipelothrix Rhusiopathiae antigen, is approximately 5 ml. 4. The mixture of claim 1 contains an antigen from Haemophilus parasuis that is effective in reducing the risk of clinical manifestations of Haemophilus parasuis infection when administered to susceptible animals. 5. The mixture of claim 4, the effective dose of Haemophilus Parasuis antigen is approximately 5 ml. 6. The mixture of claim 4, the effective dose of Haemophilus parasuis antigen, contains at least 1.5 x 107 cfu/dose. 7. The mixture of claim 1, the synergistic agent, has a mineral oil base. 8. Compound of Claim 1: This compound induces an immune response to infection by selected pathogens from a group including Haemophilus parasuis, Erysipelothrix rhusiopathiae, and their associates. 9. Vaccine for reducing the risk of clinical manifestations of Erysipelothrix Rhusiopathiae infection after single administration of the aforementioned vaccine. This vaccine consists of: a single dose of Erysipelothrix Rhusiopathiae antigen; and an adjuvant. 10. Vaccines under claim 9 that also contain a certain amount of Haemophilus Parasuis antigen. 11. Vaccine of claim 9: The stated dose of Erysipelothrix Rhusiopathiae antigen is approximately 5 ml. 12. Vaccine of claim 10: The aforementioned dose of the antigen from Haemophilus parasuis is a dose that reduces the risk of clinical manifestations of Haemophilus parasuis infection. 13. For the vaccine of claim 10, the stated dose of Haemophilus parasuis antigen is approximately 5 ml. 14. For the vaccine under claim 10, the effective dose of Haemophilus parasuis antigen is at least 1.5 x 10⁷ cfu/dose. 15. The vaccine under claim 9 contains an adjuvant with a mineral oil base. 16. Vaccine of claim 9: This vaccine reduces the risk of clinical manifestations of Erysipelothrix Rhusiopathiae infection for at least four months after administration. 17. Vaccine of Claim 10: This vaccine reduces the risk of clinical manifestations of Haemophilus parasuis infection for at least four months after administration. 18. Vaccine of Claim 10: Such vaccine induces an immune response against infection by selected pathogens from a group comprising Haemophilus parasuis, Erysipelothrix rhusiopathiae and their associates. 19. The use of a drug mixture containing a certain amount of antigen from Erysipelothrix Rhusiopathiae, a certain amount of antigen from Haemophilus Parasuis, and an excipient to reduce the risk of clinical manifestations in animals resulting from infection by selected pathogens from the group including Haemophilus Parasuis, Erysipelothrix Rhusiopathiae, and their concomitants. 20. In accordance with claim 19, the administration procedure is by intramuscular injection. 21. Using the method described in claim 19, the aforementioned dose of Erysipelothrix Rhusiopathiae antigen is approximately 5 ml. 22. In accordance with claim 19, the stated quantity of Haemophilus parasuis antigen is approximately 5 ml. 23. In accordance with claim 19, the dose of Haemophilus parasuis antigen must be at least 1.5 x 10⁷ cfu/dose. 24. In accordance with claim 19, the synergistic agent has a mineral oil base. 25. Application of Claim 19: Reduction of the risk in animals to develop clinical signs of Haemophilus parasuis and Erysipelothrix rhusiopathiae infection for a duration of at least 132 days. 26. The use of claim 19, the aforementioned administration procedure, reduces the risk in animals of developing clinical signs of infection with Haemophilus parasuis and Erysipelothrix rhusiopathiae. 27. The use of claim 19 also includes a procedure for confirming the reduction of risk in animals by challenging the animals with virulent strains of Haemophilus Parasuis or Erysipelothrix Rhusiopathiae and monitoring these animals for the occurrence of the aforementioned clinical symptoms. 28. The use of a mixture containing a certain amount of antigen from Erysipelothrix Rhusiopathiae, a certain amount of antigen from Haemophilus Parasuis, and an excipient for the production of a drug to induce an immune response to Haemophilus Parasuis or Erysipelothrix Rhusiopathiae infection. 29. In accordance with claim 28, the administration procedure is by intramuscular injection. 30. Using the provisions of claim 28, the aforementioned dose of Erysipelothrix Rhusiopathiae antigen is approximately 5 ml. 31. In accordance with claim 28, the stated quantity of Haemophilus parasuis antigen is approximately 5 ml. 32. In accordance with claim 28, the dose of Haemophilus parasuis antigen must be at least 1.5 x 10⁷ cfu/dose. 33. In accordance with claim 28, the excipient of such excipient is mineral oil-based. 34. Application of Claim 28: The immune response of such animals to infection with Haemophilus parasuis or Erysipelothrix rhusiopathiae lasts for at least 4 months. 35. The use of claim 28, the aforementioned administration procedure, induces an immune response against Haemophilus parasuis and Erysipelothrix rhusiopathiae infections. 36. The use of claim 28 also includes a procedure for confirming the animal's immune response by challenging the animal with a virulent strain of Haemophilus Parasuis or Erysipelothrix Rhusiopathiae and testing for such immune response. 37. The method of preparing the mixture consists of the following steps: preparing the mixture by combining the amount of antigen from Haemophilus Parasuis, the amount of antigen from Erysipelothrix Rhusiopathiae and the synergistic agent; and emulsifying the said mixture. 38. The method of claim 37 also includes the procedure of inactivating the sources of such antigens from Haemophilus parasuis and Erysipelothrix rhusiopathiae. 39. Method of claim 37: The aforementioned Haemophilus parasuis antigen is derived from strain Z-1517. 40. Method of claim 37: The Erysipelothrix Rhusiopathiae antigen is derived from the SE-9 variant. 41. The method of claim 37, which also includes the procedure for standardizing the mixture, is intended to provide known quantifications of Haemophilus parasuis and Erysipelothrix rhusiopathiae antigens.